Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Many of the antiretrovirals used against HIV-1 are either ineffective or less effective in HIV-2 infection. There is in vitro evidence of the potency of maraviroc and several investigational agents against HIV-2. We conclude that, whilst specific boosted protease inhibitors combined with nucleoside analogues should still be considered the mainstays of HIV-2 treatment, maraviroc, T-1249, TAK-779 and AMD3100, as well as raltegravir, could contribute to regimens for treatment-experienced individuals. Factors bearing on the use and timing of these alternative agents are discussed.

Original publication

DOI

10.3851/IMP2031

Type

Journal article

Journal

Antivir Ther

Publication Date

2012

Volume

17

Pages

435 - 438

Keywords

CCR5 Receptor Antagonists, Cyclohexanes, Female, HIV Envelope Protein gp41, HIV Fusion Inhibitors, HIV-2, Humans, Male, Peptide Fragments, Triazoles